
One of the largest randomised placebo-controlled tDCS trial conducted for Major Depressive Disorder (MDD) showed Flow tDCS device superior to sham

EMPOWER Study Overview

The study was double-blinded across 173 participants with moderate to severe depression. Each participant was given a Flow or sham device to be used in the comfort of their own homes over a 10-week treatment period. The treatment protocol utilised in the clinical trial was 3-5 stimulation sessions a week. Each session was 30 minutes long.

Preliminary results:

Over half of Flow patients were depression-free at 10 weeks



No serious adverse effects were reported.

Study conclusions and implications

This clinical trial demonstrates that using the Flow tDCS headset is an effective treatment option for MDD. In fact, when reviewing these results against antidepressant clinical trials using an odds ratio, **the Flow treatment was approximately twice as effective as the best-selling antidepressants** (3.45 vs 1.68) **and none of the side effects from antidepressants**. Further suggesting that the Flow tDCS headset is a favourable treatment alternative for MDD.



Treat depression. Differently.

Flow Neuroscience is helping transform patient and clinic outcomes with the first at-home tDCS treatment and corresponding remote monitoring system.



Spend time where it matters most

- Onboard patients in 10 minutes
- Streamline patient visits with remote monitoring insights



Add choice and flexibility

- Access to adherence and progress data anytime, anywhere
- Standalone or augment with existing treatment plans



Grow your business

- Extend services to more patient groups including treatment-resistant
- Unlock savings of £2000 per patient per year



Discover why Flow is trusted by the NHS and 100+ private clinics to drive change and to treat depression, differently.

